A Missing CBD-Glucuronide Standard Limited Hydrolysis Validation
The automated assay could quantify CBD in urine, but its developers could not directly evaluate cleavage of CBD-glucuronide because the corresponding reference standard was unavailable. Validation of one conjugate did not fill that gap.
The method included a conversion step
Frei and colleagues developed a GC–MS/MS procedure for five cannabinoids in whole blood and urine. Urine preparation included enzymatic deglucuronidation. Their discussion identified hydrolysis as relevant to urinary CBD measurement, while explaining that the CBD-glucuronide standard was not available for evaluating that step.
A free-analyte control asks a different question
A control fortified with free CBD can challenge extraction and measurement of that compound. It does not, by itself, establish how completely conjugated CBD is converted before measurement. The researchers did assess THC-COOH-glucuronide with an available standard, but that compound is not interchangeable with CBD-glucuronide as a hydrolysis challenge.
The limitation is specific
This gap does not prove that all reported CBD values were inaccurate or supply a correction percentage. It identifies a part of the workflow for which direct validation evidence was limited. For a urine result, the measured fraction and preparation procedure should accompany the concentration. The study was analytical research using biological matrices, not a trial establishing a urinary CBD threshold for clinical benefit or impaired performance.
Related analysis: the automated cannabinoid assay.
Research cited
Frei and colleagues (2022). Quantitative determination of five cannabinoids in blood and urine by gas chromatography tandem mass spectrometry applying automated on-line solid phase extraction. DOI: 10.1002/dta.3241.
